Fig. 7: FASNi is effective in KMLC in vivo.
From: Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer
a, b Representative H&E pictures of the lungs of TetO-Kras mice treated as indicated and tumor number quantification. n = number of mice. c, d In vivo growth curves and post-resection pictures of H460 and A549 xenografts in NOD/SCID mice treated as indicated. e–g Representative pictures of C11-BODIPY staining of the lungs of TetO-Kras and of H460 xenografts, and their quantification. Dotted circles in e indicate lung tumor identified via H&E staining. h Volcano plot showing lipid species identified by MS/MS differentially represented in FASNi versus vehicle (n = 5 mice/group). i In vivo growth curves and j post-resection pictures of A549 xenografts in NOD/SCID mice treated as indicated in the schematic. Color-coded statistics indicate comparisons to vehicle. Lip-1, Liproxstatin-1. In b, c, g, i data are represented as mean ± SD. In b, g unpaired two-tailed student t-test, in c, multiple t-tests followed by Benjamini–Hochberg FDR, in h generalized linear model followed by Benjamini–Hochberg FDR, and in i two-way ANOVA plus Sidak’s comparisons.
